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Abstract
Background: In observational studies, men with prostate cancer treated with gonado-
tropin-releasing hormone (GnRH) agonists had a higher risk of cardiovascular disease
(CVD) compared to men who had undergone orchiectomy. However, selection bias may
have influenced the difference in risk.
Objective: To investigate the association of type of androgen deprivation therapy (ADT)
with risk of CVD while minimising selection bias.
Design, setting, and participants: Semi-ecologic study of 6556 men who received GnRH
agonists and 3330 men who underwent orchiectomy as primary treatment during
1992–1999 in the Prostate Cancer Database Sweden 3.0.
Outcome measurements and statistical analysis: We measured the proportion of men
who received GnRH agonists as primary treatment in 580 experimental units deﬁned by
healthcare provider, diagnostic time period, and age at diagnosis. Incident or fatal CVD
events in units with high and units with low use of GnRH agonists were compared. Net
and crude probabilities were also analysed.
Results and limitations: The risk of CVD was similar between units with the highest and
units with the lowest proportion of GnRH agonist use (relative risk 1.01, 95% conﬁdence
interval [CI] 0.93–1.11). Accordingly, there was no difference in the net probability of
CVD after GnRH agonist compared to orchiectomy (hazard ratio 1.02, 95% CI 0.96–1.09).
The 10-yr crude probability of CVD was 0.56 (95% CI 0.55–0.57) for men on GnRH
agonists and 0.52 (95% CI 0.50–0.54) for men treated with orchiectomy. The main
limitation was the nonrandom allocation to treatment, with younger men with lower
comorbidity and less advanced cancer more likely to receive GnRH agonists.
Conclusion: Our data do not support previous observations that GnRH agonists increase
the risk of CVD in comparison to orchiectomy.
Patient summary: We found a similar risk of cardiovascular disease between medical
and surgical treatment as androgen deprivation therapy for prostate cancer.
* Corresponding author. Copenhagen Prostate Cancer Centre, Rigshospitalet, Ole Maaløes Vej 24, afs
7521, 2200 Copenhagen, Denmark. Tel. +45 35457125; Fax: +45 35452726.
E-mail address: thomsen.frederik@gmail.com (F.B. Thomsen).
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1. Introduction
Androgen deprivation therapy (ADT) for men with prostate
cancer [1,2] is associated with adverse effects such as bone loss
with increased risk of fractures [3–5], metabolic aberrations
with a higher risk of cardiovascular disease (CVD) [6–14], and a
higher risk of diabetes mellitus type 2 [14–16].
It was recently reported that gonadotropin-releasing
hormone (GnRH) agonists are associated with a higher risk
of CVD compared to orchiectomy [17,18]. However, the
difference in risk of CVD between GnRH agonists and
orchiectomy may have been confounded by indication for
treatment, since men who undergo orchiectomy are on
average older and have more advanced prostate cancer than
men treated with GnRH agonists, resulting in a shorter life
expectancy and less time at risk for CVD [12,17–19].
The aim of this study was to assess the association
between type of ADT and risk of CVD, while minimising
selection bias. We took advantage of a natural experiment
that took place in Sweden during the 1990s, when type of
ADT was often more influenced by the preference of the
healthcare provider than by a man’s prostate cancer
characteristics and comorbidity. We performed a semi-
ecologic study in which exposure to GnRH agonists was
assessed on a population level in experimental units defined
by healthcare provider, diagnostic time period, and age at
diagnosis, with outcomes assessed on an individual level
[20,21]. We also analysed crude and net probability, with
exposure and outcome assessed on an individual level [22].
2. Patients and methods
Prostate Cancer Data Base Sweden (PCBaSe) 3.0 contains information on
cancer characteristics and primary treatment from the National Prostate
Cancer Register (NPCR) of Sweden [23,24]. Information on comorbidity
from the Patient Registry and data on educational level, income, and
marital status were obtained from the LISA database, and cause and date
of death were obtained from the Cause of Death Registry [23,25–31].
The current study included men diagnosed with prostate cancer
during 1992–1999 who received GnRH agonists or bilateral orchiectomy
as primary treatment (Supplementary Fig. 1).
No data on the date of treatment are available in the NPCR. Therefore,
we assessed the time from diagnosis to start of treatment using data
from a later calendar period (2006–2012) when these dates were
available from other sources. Information in the Prescribed Drug
Registry (which started in 2005) for date of ﬁrst ﬁlled prescription for
GnRH agonist and data in the Patient Registry (which reached high
capture of orchiectomy procedures in the mid-2000s) showed that 90%
of men had received their primary treatment within 3 mo after the date
of diagnosis. Therefore, follow-up in the current study was started 3 mo
after the date of prostate cancer diagnosis, and the men were followed
until the event of interest, death, emigration, or end of the study period
(December 31, 2013), whichever event came ﬁrst.
The CVD endpoint was identiﬁed as the ﬁrst occurrence of a CVD
diagnosis (ICD-10 codes I00–I99), including hypertension (I10–I15),
ischaemic heart disease (I21–I25), stroke (I60–I64, G45), deep venous
thrombosis or pulmonary embolism (I80–I93, I26), and arterial
embolism (I74, K55), in the Patient Registry or Cause of Death Registry.
The associations between GnRH agonists or orchiectomy and
fractures (SX2) and diabetes (E10–E14) were also assessed.
The research ethics board at Umea˚ University Hospital approved the
study.
2.1. Statistical methods
Differences in characteristics between the treatment groups were tested
using the x2 test for categorical variables and the Mann-Whitney U test
for continuous variables.
Three analytical approaches were used to compare risk of CVD between
men treated with GnRH agonists and men treated with orchiectomy. First, a
semi-ecologic study design was applied to assess exposure to treatment on
a group level in an attempt to minimise selectionbias [20,21]. Exposure was
measured as the proportion of men who received GnRH agonists in
experimental units deﬁned by healthcare provider, 2-yr diagnostic time
period, and age at diagnosis (<70, 70–74, 75–79, 80+ yr). For each of the
580 experimental units, the number of eventsand person-years atrisk were
calculated. A Poisson model with the logarithm of person-years at risk as
the offset was used to assess the association between the proportion of men
who received GnRH agonists, included as a restricted cubic spline, and the
risk of a CVD event, with prostate-speciﬁc antigen (PSA), T stage,
metastases, previous CVD, hypertension, and previous diabetes within
5 yr from diagnosis as covariates. Results are presented as relative risk (RR)
with 95% conﬁdence interval (CI).
Using individual data on exposure and outcome, the crude and net
probability of CVD were estimated. The crude probability of death from
prostate cancer and death from causes unrelated to CVD were calculated in
a competing-risks analysis [32]. The net probability of CVD was estimated
using the Kaplan-Meier method, and the hazard ratio (HR) and 95% CI were
estimated with multivariable Cox proportional hazards models using age
as the time scale and censoring observations at the time of the occurrence
of a competing event (ie, death from other causes) [33]. The multivariable
model included type of treatment (GnRH agonist vs orchiectomy), year of
diagnosis (continuous), PSA (categorical), stage (categorical), metastases
(categorical), and previous CVD (yes vs no), hypertension (yes vs no), and
diabetes (yes vs no) within 5 yr from diagnosis.
All tests were two-sided and the signiﬁcance level was set to
p < 0.05. Statistical analysis was performed using R version 3.1.2 (R
Foundation for Statistical Computing, Vienna, Austria).
3. Results
The study population consisted of 6556 men who received
GnRH agonists and 3330 men who underwent orchiectomy
as primary treatment. The median follow-up for men alive at
the end of follow-up was 16 yr and there was a total of 46 012
person-years of follow-up. There was a sevenfold difference
in use of GnRH agonists between experimental units with the
lowest and the highest use (14% vs 96%). The use of GnRH
agonists increased during the study period (Fig. 1). Men
treated with GnRH agonists were younger and had a higher
proportion of nonmetastatic disease, lower serum PSA levels,
fewer previous CVD events. and higher educational level in
comparison to men who underwent orchiectomy (Supple-
mentary Table 1). These differences were smaller when
comparing units with high and low use of GnRH agonists, but
in the same direction as in the direct comparison between
men treated with GnRH agonists and orchiectomy (Table 1).
3.1. CVD risk according to type of ADT exposure in experimental
units
The CVD risk was similar for men treated in units with the
highest proportion of GnRH agonist use and men treated in
units with the lowest use (RR 1.01, 95% CI 0.93–1.11; Fig. 2
and Table 2).
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Fig. 1 – Percentage of men who received gonadotropin-releasing hormone (GnRH) agonists as primary treatment (ADT) by healthcare provider and time
period in Prostate Cancer data Base Sweden (PCBaSe) 3.0. Men diagnosed by healthcare provider with <15 cases of primary androgen deprivation
therapy per year during the specific time period were excluded (red rectangles). The National Prostate Cancer Register captured men diagnosed with
prostate cancer in the Northern region from 1992, the Southeastern region from 1994, the Western, Southern, and Uppsala O¨rebro regions from 1996,
and the Stockholm region from 1998.
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Table 1 – Baseline characteristics for men with prostate cancer in
Sweden 3.0 who received GnRH agonists or orchiectomy as
primary treatment
GnRH agonists as primary treatment in
experimental unit
0–33% 34–66% 67–100%
Year of diagnosis
1992–1993 31 (0–100) 12 (0–0) 2 (0–0)
1994–1995 19 (0–0) 11 (0–0) 6 (0–0)
1996–1997 41 (0–100) 34 (0–100) 31 (0–100)
1998–1999 9 (0–0) 43 (0–100) 61 (0–100)
Age at diagnosis
Median 80 (75.5–83) 77 (72–82) 74 (66–77)
<70 yr 5 (0–0) 11 (0–0) 30 (0–100)
70–74 yr 11 (0–0) 23 (0–100) 22 (0–100)
75–79 yr 30 (0–100) 29 (0–100) 24 (0–0)
80+ yr 54 (0–100) 37 (0–100) 24 (0–0)
T stage
T1a/b 3 (0–6) 2 (0–5) 2 (0–0)
T1c 2 (0–0) 4 (0–7) 6 (0–9)
T2 29 (14–48) 24 (15–36) 25 (12–39)
T3 51 (33–62) 52 (40–62) 52 (40–64)
T4 12 (0–19) 15 (5–21) 13 (0–20)
TX/missing 2 (0–0) 2 (0–3) 2 (0–0)
N stage
N0 2 (0–0) 3 (0–4) 2 (0–3)
N1 2 (0–0) 3 (0–6) 6 (0–11)
NX/missing 96 (94–100) 94 (91–100) 91 (83–100)
M stage
M0 20 (5–31) 25 (12–37) 31 (14–43)
M1 34 (22–48) 37 (25–52) 34 (21–50)
MX/missing 46 (22–67) 38 (13–56) 35 (12–50)
Prostate–speciﬁc antigen
Median 87 (63.5–135.5) 79 (55–113) 65 (48.8–105.1)
<25 ng/ml 17 (7–22) 18 (10–23) 22 (11–29)
25–<50 ng/ml 16 (7–24) 19 (12–25) 19 (10–26)
50–<100 ng/ml 18 (10–25) 17 (11–25) 19 (11–26)
100–<200 ng/ml 15 (6–19) 14 (6–19) 13 (6–20)
200–<500 ng/ml 13 (4–20) 14 (6–19) 12 (6–18)
500 ng/ml 14 (5–22) 16 (9–21) 13 (6–20)
Missing 7 (0–10) 3 (0–5) 2 (0–0)
Gleason score a
2–6 18 (6–24) 18 (8–25) 18 (9–27)
7 44 (30–55) 40 (27–54) 41 (28–50)
8–10 35 (24–48) 39 (25–50) 39 (26–50)
Missing 4 (0–6) 3 (0–5) 3 (0–4)
Charlson comorbidity index
0 65 (57–75) 65 (59–77) 67 (58–79)
1 18 (10–24) 19 (11–24) 17 (9–22)
2+ 17 (10–22) 16 (8–21) 16 (7–22)
Previous conditions within 5 yr before diagnosis
Cardiovascular disease
Yes 33 (22–41) 31 (19–40) 28 (17–37)
No 67 (59–78) 69 (60–81) 72 (63–83)
Hypertension
Yes 6 (0–9) 7 (0–10) 6 (0–10)
No 94 (91–100) 93 (90–100) 94 (90–100)
Diabetes
Yes 5 (0–10) 6 (0–10) 5 (0–7)
No 95 (90–100) 94 (90–100) 95 (93–100)
Education level
Low 57 (50–75) 59 (52–70) 54 (44–68)
Middle 15 (5–22) 22 (12–31) 27 (15–36)
High 5 (0–10) 8 (0–14) 11 (0–17)
Missing 23 (0–33) 11 (0–13) 8 (0–6)
Marital status
Unmarried 10 (0–15) 9 (0–12) 9 (1–15)
Married 63 (55–77) 65 (57–75) 69 (61–78)
Divorced 4 (0–6) 7 (0–12) 9 (0–14)
Widower 22 (7–29) 18 (4–25) 13 (0–17)
Missing 0 (0–0) 0 (0–0) 0 (0–0)
Table 1 (Continued )
GnRH agonists as primary treatment in
experimental unit
0–33% 34–66% 67–100%
Primary treatment
GnRH agonists 19 (11–28) 53 (45–61) 87 (79–100)
Orchiectomy 81 (72–89) 47 (39–55) 13 (0–21)
GnRH = gonadotropin-releasing hormone.
Data are presented as total percentage/median with interquartile range
between experimental units (ie, combination of year, hospital and age
group) in parentheses.
a World Health Organisation grade converted to Gleason score using the
rule G1 = GS 2–6, G2 = GS 7, and G3 = GS 8–10.
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Fig. 2 – Relative risk of cardiovascular disease (CVD) according to the
percentage of men who received gonadotropin-releasing hormone
(GnRH) agonists as primary treatment in each experimental unit. The
orange shading shows the 95% confidence interval. CVD was defined as first
occurrence of CVD (ICD-10 codes I00–I99). The total number of CVD events
was 5145, including 31% incident cases of other forms of heart disease (I30–
I52), 26% ischaemic heart disease (I20–I25), 15% cerebrovascular disease
(I60–I69), 11% hypertensive disease (I10–I15), 8% disease of the veins,
lymphatic vessels, and lymph nodes (I80–I89), 5% disease of the arteries,
arterioles, and capillaries (I70–I79), 3% pulmonary heart disease and disease
of the pulmonary circulation (I26–I28), and 1% others and unspecified (I00–
I09, I95–I99). Death from CVD was reported as the first occurrence of CVD
in 8% of the men.
Table 2 – Relative risk of cardiovascular disease/death by
percentage exposure to GnRH agonists
RR (95% CI) p value
GnRH agonists
0–33% 1.00 (reference) –
34–66% 1.04 (0.94–1.14) 0.5
67–100% 1.01 (0.93–1.11) 0.8
GnRH = gonadotropin-releasing hormone; RR = relative risk; CI = conﬁdence
interval.
Risk estimated using ah Poisson model adjusted for T stage, M stage, Gleason
score, prostate-speciﬁc antigen, previous cardiovascular disease, previous
hypertension, and previous diabetes.
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3.2. Crude probability of CVD according to type of ADT
In total, 5145 CVD events were registered. The crude
probability for CVD at 1 yr after diagnosis was lower for
men on GnRH agonists (0.13 95% CI 0.12–0.14) than for men
treated with orchiectomy (0.15, 95% CI 0.14–0.16) but was
higher at 10-yr follow-up (0.56, 95% CI 0.55–0.57 vs 0.52,
95% CI 0.50–0.54; Fig. 3A,B). The 10-yr probability of death
from prostate cancer was lower for men on GnRH agonists
(0.31, 95% CI 0.30-0.32) than for men undergoing orchiec-
tomy (0.37, 95% CI 0.35–0.39), but similar for death from
other causes (0.06, 95% CI 0.06–0.07 vs 0.07, 95% CI
0.06–0.08).
3.3. Net probability of CVD according to type of ADT
In a multivariable Cox proportional hazards model, risk of
CVD was similar for men treated with GnRH agonists and
men treated with orchiectomy, (HR 1.02, 95% CI 0.96–1.09;
Table 3). The CVD risk was higher among men with previous
CVD (HR 2.03, 95% CI 1.90–2.17) and men with diabetes (HR
1.50, 95% CI 1.32–1.71). In an analysis restricted to CVD
death as outcome, there was a higher risk after orchiectomy
compared to GnRH agonists on univariable analysis
(Supplementary Fig. 2) but not multivariable analysis
(Supplementary Table 2). There was a lower net probability
of CVD during the first year after diagnosis for men on GnRH
agonists compared to orchiectomy, and for prostate cancer
death during the first 2 yr, whereas in subsequent follow-up
the cumulative risks essentially increased in parallel
(Fig. 3C.D). Finally, the risk of death from other causes
was slightly higher after orchiectomy compared to GnRH
agonists (Fig. 3E). Analyses stratified according to M stage
and previous CVD yielded similar results as the main
analyses (Supplementary Table 3). The risk of CVD as a
continuous function of year of diagnosis was 1.02 (95% CI
1.00–1.04; p = 0.017).
4. Discussion
In this semi-ecologic, nationwide, population-based study,
no evidence of higher risk of incident or fatal CVD was found
for men on GnRH agonists compared to men who
underwent orchiectomy. Supporting results were obtained
in analyses of crude and net probabilities of CVD, with both
exposure and outcome assessed on an individual level.
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Fig. 3 – (A,B) Crude probability of death from cardiovascular disease (CVD), prostate cancer, or other causes for men who (A) received GnRH agonists
and (B) underwent orchiectomy. (C–E) Net probability of (C) cardiovascular disease or death from cardiovascular disease, (D) death from prostate
cancer, and (E) death from other causes for men who received GnRH agonists or orchiectomy. The crude probability is from competing-risks analysis
of a CDV event and the competing events of death from prostate cancer and other causes. The net probability is from Kaplan-Meier analysis of CVD,
prostate cancer death, and other causes of death.
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The main limitation of the present study regarding
exposure was the nonrandom allocation to type of ADT,
with ensuing selection bias for younger and healthier men
with less advanced cancer to receive GnRH agonists. Thus,
despite the semi-ecologic design, residual confounding
cannot be excluded. Since the NPCR does not register date of
treatment, we started follow-up 3 mo after the date of
diagnosis, at which time point 90% of men diagnosed in a
later calendar period had received their primary treatment.
There was no information on duration and adherence to
GnRH agonists, but it is rare for men with advanced prostate
cancer to stop ADT. We also lacked information on smoking,
body mass index, and use of cardiovascular drugs. Limita-
tions regarding the endpoints are that we used administra-
tive data from the Patient Registry and the Cause of Death
Registry to define CVD events. However, several investiga-
tions have shown high validity for diagnosis of CVD (eg,
heart failure, acute myocardial infarction, and stroke) [34–
37] and there are no reasons to assume a systematic bias
according to type of ADT. Strengths of the study included
the nationwide, population-based cohort of men with
comprehensive data from several high-quality health care
registers [23–26] as well as the use of three different
statistical methods to assess the association between type
of ADT and risk of CVD.
In accordance with previous studies, men treated with
orchiectomy for prostate cancer in the current study were
older, had more comorbidities, and presented with more
advanced stage of prostate cancer compared to men treated
with GnRH agonists [12,17–19]. A meta-analysis including
12 randomised clinical trials found no difference in overall
or prostate cancer survival between men treated with GnRH
agonists and orchiectomy [38]. Accordingly, the higher rate
of prostate cancer death among men treated with orchiec-
tomy in our study was the result of more advanced cancer in
comparison to men on GnRH agonists, which in turn
influenced the risk of CVD. The semi-ecologic study design
decreased the influence of an individual’s cancer character-
istics and general health on selection of ADT, but did not
fully eliminate it. However, the risk of CVD among men
treated in units with high use of GnRH agonists was similar
to that in units with low use.
In separate analyses, we determined the net and crude
probability of death from CVD, prostate cancer, and other
causes. Crude probability is estimated using a competing-
risks analysis in which death from causes other than the
Table 3 – Multivariable Cox proportional hazards models* of cardiovascular disease, fractures, and diabetes
CVD a (n = 5145) Fracture (n = 1262) Diabetes b (n = 705)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Primary treatment
Orchiectomy 1.00 (reference) 1.00 (reference) 1.00 (reference)
GnRH agonists 1.02 (0.96–1.09) 0.5 0.91 (0.80–1.04) 0.16 1.02 (0.85–1.22) 0.8
Year of diagnosis (continuous) 1.02 (1.00–1.04) 0.017 1.11 (1.07–1.15) <0.001 1.02 (0.98–1.07) 0.3
T stage
T1 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
T2 0.97 (0.86–1.09) 0.6 0.88 (0.70–1.09) 0.2 1.20 (0.86–1.67) 0.3
T3 0.97 (0.87–1.09) 0.6 0.89 (0.72–1.11) 0.3 1.22 (0.89–1.68) 0.2
T4 1.02 (0.89–1.17) 0.8 1.07 (0.82–1.40) 0.6 1.19 (0.80–1.76) 0.4
M stage
M0/MX 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
M1 1.00 (0.93–1.08) 0.9 1.32 (1.14–1.53) <0.001 1.06 (0.87–1.29) 0.6
Prostate-speciﬁc antigen
<25 ng/ml 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
25–<50 ng/ml 0.97 (0.89–1.05) 0.5 1.04 (0.88–1.23) 0.7 0.83 (0.67–1.04) 0.11
50–<100 ng/ml 1.03 (0.95–1.12) 0.5 1.00 (0.84–1.19) 1 0.86 (0.68–1.08) 0.19
100–<200 ng/ml 1.07 (0.97–1.18) 0.19 1.22 (1.01–1.49) 0.043 0.83 (0.63–1.09) 0.18
200–<500 ng/ml 1.09 (0.98–1.22) 0.11 1.11 (0.89–1.38) 0.4 1.25 (0.96–1.63) 0.10
500 ng/ml 1.05 (0.93–1.18) 0.4 1.01 (0.79–1.29) 0.9 0.93 (0.68–1.28) 0.7
Gleason score
2–6 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
7 1.01 (0.93–1.08) 0.9 1.09 (0.94–1.27) 0.2 1.18 (0.96–1.44) 0.12
8–10 1.10 (1.01–1.18) 0.022 1.09 (0.93–1.27) 0.3 1.20 (0.97–1.49) 0.09
Previous CVD c
No 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
Yes 2.03 (1.90–2.17) <0.001 1.04 (0.90–1.21) 0.6 1.11 (0.91–1.35) 0.3
Previous hypertension c
No 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
Yes 1.13 (1.00–1.28) 0.051 1.14 (0.88–1.49) 0.3 1.33 (0.93–1.91) 0.12
Previous diabetes c
No 1.00 (reference) – 1.00 (reference) –
Yes 1.50 (1.32–1.71) <0.001 1.43 (1.08–1.88) 0.012
CVD = cardiovascular disease; GnRH = gonadotropin-releasing hormone.
* All models performed with age as time-sale.
a A total of 564 (11%) men had hypertension as their ﬁrst CVD event.
b Only men without previous diabetes before their prostate cancer diagnosis.
c Within 5 yr before prostate cancer diagnosis.
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event of interest is treated as a competing event. Thus, the
crude probability of CVD will be decreased by a high
number of competing events (eg, death from prostate
cancer). At 10-yr follow-up, men on GnRH agonists in our
study had a higher probability of CVD and a lower
probability of prostate cancer death in comparison to
men who underwent orchiectomy.
Net probability refers to the hypothetical situation in
which only the event of interest can occur. All other events
are censored and there is no influence from competing
events on risk; this is the preferred study design for
investigating causality [39]. We found that the net
probability of both CVD and prostate cancer death were
higher for men who underwent orchiectomy than for men
on GnRH agonists. The results from these head-to-head
comparisons are in accordance with a Chinese study of
297 men on GnRH agonists and 387 men who underwent
orchiectomy [19]. Furthermore, previous studies using
PCBaSe that included 5000 men who underwent orchiecto-
my and 20 000 men on GnRH agonists showed that these
two ADT modalities were associated with a similar increase
in CVD risk and fracture risk in comparison to the
background male population [5,12,13,40].
By contrast, our results differ from those of three other
large observational studies [14,17,18]. Two of the studies, a
Surveillance, Epidemiology and End Results (SEER)–Medi-
care database study including 73 196 men with locoregional
prostate cancer [14] and a Danish nationwide, population-
based study including more than 30 000 prostate cancer
cases [18], investigated the risk of CVD for men managed
with orchiectomy or medical ADT (in the Danish study both
GnRH agonists and antiandrogens) to that for men with
prostate cancer not on ADT. Both studies found a higher risk
of CVD for men on GnRH agonists compared to men not on
ADT, whereas the risk of CVD was similar for men who had
undergone orchiectomy and men not on ADT.
The third study, also a SEER study, included men with
metastatic prostate cancer primarily managed with ADT
during a 15-yr period, of whom 2866 men received GnRH
agonists and 429 men underwent orchiectomy. In a direct
comparison between the two ADT modalities, the crude
probability of CVD and of fractures and diabetes was lower
after orchiectomy in comparison to GnRH agonists [17]. It is
difficult to conceive a biological mechanism for the lower risk
of fractures after orchiectomy compared to GnRH agonists.
The risk of fractures increases with lower levels of androgens
[41,42] and, on average, androgen levels are slightly higher in
men on GnRH agonists than in men who have undergone
orchiectomy [43]. Thus, confounding is a likely explanation
for the unexpected results for fractures and could also have
contributed to the association with CVD. Furthermore, in this
SEER study, there was no statistically significant difference in
net probability, the preferred method for investigation of
causality, between GnRH agonists and orchiectomy for any
outcome, in accordance with our results.
Taken together, the results from our study and all the
cited studies do not provide evidence that warrants a
change in the recommendations for use of ADT for advanced
prostate cancer from GnRH agonists to orchiectomy.
5. Conclusions
In this nationwide, population-based observational study
there was no increase in the risk of CVD among men on
GnRH agonists compared to men who had undergone
orchiectomy in three separate analytical approaches. Our
study provides no evidence in favour of changing the
current standard ADT for prostate cancer.
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